BR112017024264A2 - ?composições para transplante de flora fecal e métodos de preparação e utilização das mesmas, e dispositivos para suaadministração? - Google Patents

?composições para transplante de flora fecal e métodos de preparação e utilização das mesmas, e dispositivos para suaadministração?

Info

Publication number
BR112017024264A2
BR112017024264A2 BR112017024264A BR112017024264A BR112017024264A2 BR 112017024264 A2 BR112017024264 A2 BR 112017024264A2 BR 112017024264 A BR112017024264 A BR 112017024264A BR 112017024264 A BR112017024264 A BR 112017024264A BR 112017024264 A2 BR112017024264 A2 BR 112017024264A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
administration
preparing
devices
Prior art date
Application number
BR112017024264A
Other languages
English (en)
Other versions
BR112017024264B1 (pt
Inventor
Julius Borody Thomas
Original Assignee
Crestovo Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crestovo Holdings Llc filed Critical Crestovo Holdings Llc
Publication of BR112017024264A2 publication Critical patent/BR112017024264A2/pt
Publication of BR112017024264B1 publication Critical patent/BR112017024264B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

a presente invenção se refere às composições, por exemplo, formulações, utilizadas para tratamentos gástricos, gastrointestinais e/ou colónicos, e métodos para preparação, armazenamento e utilização, incluindo seu armazenamento, o seu armazenamento a longo prazo em temperatura ambiente. as composições da presente invenção são úteis para o tratamento de várias doenças ou condições, tais como distúrbio do espectro do autismo, doença de crohn, colite ulcerativa, síndrome do intestino irritável e infecções por c. difficile recorrente ou primária.
BR112017024264-8A 2015-05-14 2016-05-16 Composições para transplante de flora fecal e métodos de preparação e utilização das mesmas, e dispositivos para sua administração BR112017024264B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562161826P 2015-05-14 2015-05-14
US62/161,826 2015-05-14
PCT/US2016/032695 WO2016183577A1 (en) 2015-05-14 2016-05-16 Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them

Publications (2)

Publication Number Publication Date
BR112017024264A2 true BR112017024264A2 (pt) 2018-07-24
BR112017024264B1 BR112017024264B1 (pt) 2022-07-12

Family

ID=57249384

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017024264-8A BR112017024264B1 (pt) 2015-05-14 2016-05-16 Composições para transplante de flora fecal e métodos de preparação e utilização das mesmas, e dispositivos para sua administração

Country Status (11)

Country Link
US (4) US9901603B2 (pt)
EP (1) EP3294307A4 (pt)
JP (3) JP6692897B2 (pt)
KR (2) KR20180026376A (pt)
CN (2) CN107949391B (pt)
AU (2) AU2016262615C1 (pt)
BR (1) BR112017024264B1 (pt)
CA (1) CA2985827A1 (pt)
HK (2) HK1247840A1 (pt)
MX (1) MX2017014488A (pt)
WO (1) WO2016183577A1 (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
WO2011094027A1 (en) 2010-02-01 2011-08-04 Hlavka Edwin J Bacteriotherapy for clostridium difficile colitis
CA2807242C (en) 2010-08-04 2017-05-02 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
BR112013022927A2 (pt) 2011-03-09 2016-12-06 Univ Minnesota composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
CN108243608A (zh) 2015-05-22 2018-07-03 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法
US10799539B2 (en) * 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
FR3045383B1 (fr) 2015-12-18 2019-06-14 Maat Pharma Procede de lyophilisation d'un echantillon de microbiote fecal
CN106974940B (zh) * 2016-01-15 2020-08-25 深圳华大生命科学研究院 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) * 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
CA3045026A1 (en) * 2016-12-06 2018-06-14 Whole Biome Inc. Methods and compositions relating to isolated and purified microbes
CN106755442A (zh) * 2016-12-30 2017-05-31 苏州普瑞森基因科技有限公司 一种粪便微生物样品dna保存液
WO2018187272A1 (en) 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
EP3606541A1 (en) 2017-04-05 2020-02-12 Crestovo Holdings LLC Compositions and methods for treating parkinson's disease (pd) and related disorders
US20210095244A1 (en) * 2017-04-28 2021-04-01 Emma Allen-Vercoe Methods and Compositions for Storing Bacteria
CA3064773A1 (en) * 2017-05-26 2018-11-29 Crestovo Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
EP3664823A4 (en) 2017-08-07 2021-05-12 Finch Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MAINTAINING AND RESTORING A HEALTHY INTESTINAL BARRIER
EP3443967A1 (de) * 2017-08-17 2019-02-20 Labor L + S Aktiengesellschaft Verfahren zur einlagerung der bakterienflora des darms eines lebewesens, insbesondere eines menschen
BR112020017090A8 (pt) * 2018-02-23 2022-07-05 Crestovo Holdings Llc Imunoterapias relacionadas com microbioma
CN110740740A (zh) * 2018-02-28 2020-01-31 肠内菌群移植临床研究株式会社 含有活体微生物的组合物及其制备方法
WO2019200271A1 (en) 2018-04-13 2019-10-17 White Dog Labs, Inc. An improved method for selecting probiotics
CN108686292A (zh) * 2018-05-28 2018-10-23 重庆大学 一种释药胶囊
KR20210021023A (ko) * 2018-06-14 2021-02-24 리바이오틱스, 인코퍼레이티드 미생물총 회복 요법 조성물 및 제조 방법
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CN108676704A (zh) * 2018-07-30 2018-10-19 骆奇 一种肠道内容物分离回收装置、方法及其产品
CN108949631A (zh) * 2018-07-30 2018-12-07 骆奇 一种核孔膜在肠道内容物分离中的应用
KR102479275B1 (ko) * 2018-08-20 2022-12-21 주식회사 바이오뱅크힐링 대변세균총이식 조성물을 제조하는 방법, 및 그의 의약 용도
AU2019351017A1 (en) 2018-09-27 2021-04-29 Finch Therapeutics Holdings Llc. Compositions and methods for treating epilepsy and related disorders
EP3669944B1 (en) * 2018-12-21 2023-12-20 Salomon Amar Use of akkermansia in the treatment of oral diseases
ES2769628B2 (es) * 2018-12-26 2020-11-25 Consejo Superior Investigacion Bacteria de Holdemanella sp. y uso de la misma
CN109628311A (zh) * 2018-12-28 2019-04-16 美霖佳生物医学科技(苏州)有限公司 用于保护肠道菌的冻干保护剂、冻干粉、胶囊及其制备方法
WO2020198808A1 (en) * 2019-04-03 2020-10-08 Commonwealth Scientific And Industrial Research Organisation Methods and compositions for promoting health in a subject
EA202193075A1 (ru) * 2019-05-10 2022-02-17 4Д Фарма Рисерч Лимитед Композиции, содержащие бактериальные штаммы
WO2021003535A1 (en) * 2019-07-11 2021-01-14 Milis Antony Method for gut mucosa preparation to enhance microbial engraftment
US20230068960A1 (en) * 2019-09-24 2023-03-02 Prolacta Bioscience, Inc. Compositions and methods for treatment of inflammatory and immune diseases
CA3158132A1 (en) * 2019-10-18 2021-04-22 Finch Therapeutics Holdings Llc Compositions and methods for delivering a bacterial metabolite to a subject
CN110791435A (zh) * 2019-11-23 2020-02-14 厦门承葛生物科技有限公司 一种低温冻存保存液
WO2021142347A1 (en) * 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for non-alcoholic steatohepatitis (nash)
US20230201265A1 (en) * 2020-03-31 2023-06-29 Finch Therapeutics Holdings Llc Compositions comprising non-viable fecal microbiota and methods of use thereof
CN111681733A (zh) * 2020-04-30 2020-09-18 厦门承葛生物科技有限公司 一种肠道菌群移植供体的筛选方法
WO2022051610A1 (en) * 2020-09-04 2022-03-10 Ferring B.V. Microbiota restoration therapy (mrt) compositions and methods of manufacture
US11098377B1 (en) * 2020-09-15 2021-08-24 Nubiyota Llc Systems and methods for characterizing compositions comprising bacterial populations
CN111888381A (zh) * 2020-09-18 2020-11-06 广西细微生物科技有限责任公司 一种肠道微生物移植工艺
EP4058056A1 (en) * 2020-10-07 2022-09-21 Valneva Sweden AB Cholera vaccine formulation
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
EP4281090A1 (en) * 2021-01-21 2023-11-29 Vedanta Biosciences, Inc. Compositions and methods for treating hepatic encephalopathy
KR102272616B1 (ko) * 2021-03-25 2021-07-05 주식회사 엔테로바이옴 피컬리박테리움 프로스니치 균주를 포함하는 근위축증 예방 또는 치료용 약학적 조성물
KR102329853B1 (ko) * 2021-03-25 2021-11-23 주식회사 엔테로바이옴 아커만시아 뮤시니필라 균주를 포함하는 근위축증 예방 또는 치료용 약학적 조성물
CN113209039A (zh) * 2021-04-22 2021-08-06 重庆晶云生物科技有限公司 一种肠菌胶囊及其制备方法
KR102331482B1 (ko) * 2021-08-02 2021-12-01 주식회사 바이오뱅크힐링 루미노코쿠스 브로미 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102452957B1 (ko) * 2022-03-14 2022-10-11 한동대학교 산학협력단 프로바이오틱스 균주를 유효성분으로 포함하는 클로스트리디오이데스 디피실레 감염을 예방 또는 치료하기 위한 조성물
TW202400235A (zh) * 2022-05-13 2024-01-01 國立大學法人東京大學 治療或診斷炎症性腸疾病(ibd)之方法及組合物
WO2023229987A1 (en) 2022-05-25 2023-11-30 Neuvian LLC Vaginal care compositions comprising exosomes and its uses for improving vaginal health
CN116836880B (zh) * 2023-07-24 2023-11-28 中山大学 一种普氏梭杆菌及其应用

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1118403B (de) 1960-01-27 1961-11-30 Hoechst Ag Verfahren zur Gewinnung von antitumorwirksamen Sporen
FR1275M (fr) 1961-05-06 1962-05-02 Rene Roger Médicament a base de colibacilles vivants.
BE634858A (pt) 1962-07-19 1900-01-01
FR2828M (fr) 1963-03-01 1964-11-02 Lucien Nouvel Médicament renfermant des colibacilles antibiorésistants.
FR5528M (pt) 1965-10-01 1967-11-13
GB1271674A (en) 1968-07-09 1972-04-26 Nisshin Flour Milling Co Process and preparation for treating diarrhoea in pigs
SE371209B (pt) 1969-10-13 1974-11-11 Cernelle Ab
DE2134179A1 (de) 1971-07-09 1973-01-25 Rolf Dr Schuler Bifidobakterien enthaltendes praeparat und verfahren zur herstellung desselben
FR2244464A1 (en) 1973-06-26 1975-04-18 Serozym Laboratoires Yeast, lacto- and colibacillus based compsns - used to modify intestinal flora, treat colitis and digestive disorders, etc.
US4098728A (en) 1976-01-02 1978-07-04 Solomon Rosenblatt Medical surgical sponge and method of making same
US4335107A (en) 1978-06-05 1982-06-15 Snoeyenbos Glenn H Mixture to protect poultry from salmonella
CH637297A5 (fr) 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
US4536409A (en) 1981-01-23 1985-08-20 American Can Company Oxygen scavenger
US4452779A (en) 1982-02-03 1984-06-05 Cockerill Vernon Composition and method of treating lactating mammals
FI840816A0 (fi) 1984-03-01 1984-03-01 Farmos Oy Bakteriepreparat
JPS615022A (ja) 1984-06-19 1986-01-10 Advance Res & Dev Co Ltd 腸内細菌叢改善剤
US4892731A (en) 1986-12-11 1990-01-09 Tadashi Arai Biological intestinal antiseptics
IL86859A (en) 1987-07-10 1991-12-15 E Z Em Inc Aqueous cathartic solution containing inorganic salts
US4948734A (en) 1987-08-12 1990-08-14 Mycogen Corporation Novel isolates of bacillus thuringiensis having activity against nematodes
DE68928665T2 (de) 1988-08-02 1998-11-12 Gastro Services Pty Ltd Behandlung von gastro-intestinalen krankheiten
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5213807A (en) 1990-05-03 1993-05-25 Chemburkar Pramod B Pharmaceutical composition containing ibuprofen and a prostaglandin
JP2961184B2 (ja) 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
US5266315A (en) 1990-05-07 1993-11-30 Kabushiki Kaisha Miyarisan Seibutsu Igaku Kenkyusho Composite for Clostridium difficile diarrhea and pseudomembranous colitis
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
JP3047143B2 (ja) 1992-04-24 2000-05-29 堀井薬品工業株式会社 腸管洗浄液用組成物及び腸管洗浄液
JP3850891B2 (ja) 1994-03-01 2006-11-29 ゼリア新薬工業株式会社 緩下効果を有する組成物
JPH07242557A (ja) 1994-03-03 1995-09-19 Ss Pharmaceut Co Ltd 乳酸菌含有瀉下薬組成物
US6984513B2 (en) 1994-03-03 2006-01-10 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
DK0760848T3 (da) 1994-05-26 1998-09-23 Bracco Spa Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
US5800821A (en) 1995-03-10 1998-09-01 New England Medical Center Hospitals, Inc. Bacterial spores as a heat stable vaccine delivery system
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5858356A (en) 1995-12-21 1999-01-12 Abbott Laboratories Lactobacillus acidophilus to inhibit cryptosporidiosis in mammals
US5902578A (en) 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
US5837238A (en) 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US6087386A (en) 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
WO1998013068A1 (fr) 1996-09-26 1998-04-02 Vladimir Borisovich Kuperman Medicament prophylactique 'trisan'
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US6162464A (en) 1997-03-31 2000-12-19 Inkine Pharmaceutical, Inc. Non-aqueous colonic purgative formulations
US7374753B1 (en) 1997-06-03 2008-05-20 Ganeden Biotech, Inc. Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS
US6428783B1 (en) 1998-03-11 2002-08-06 Medtech Center, Inc. Bank of autochthonous strains of microorganisms and methods of its use for recovery of intestinal microbiocenosis of the men
US5902743A (en) 1998-03-20 1999-05-11 Wisconsin Alumni Research Foundation Probiotic bifidobacterium strain
CN1300318A (zh) 1998-05-06 2001-06-20 中村启次郎 含有性质不同且彼此共生的微生物和其代谢物的微生物培养物,含有该培养物活性组分的载体和吸附剂及其用途
US6368591B2 (en) 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
AT407008B (de) 1998-08-06 2000-11-27 Viernstein Helmut Dr Formulierungen mit probiotisch wirksamen mikroorganismen
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
CA2343051A1 (en) 1998-09-17 2000-03-23 North American Vaccine, Inc. Streptococcal c beta protein compositions
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
CN1183904C (zh) 1999-02-26 2005-01-12 盐野义制药株式会社 改进了服用性的咀嚼型软胶囊剂及其制法
FR2808689B1 (fr) 2000-05-11 2004-09-03 Agronomique Inst Nat Rech Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
US20040062757A1 (en) 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US6756032B1 (en) 2000-07-12 2004-06-29 The Procter & Gamble Company Method to enhance and/or prolong the effects of a primary challenge to a responsive system with a secondary challenge
AU2001272369A1 (en) 2000-07-17 2002-01-30 Chr. Hansen A/S Methods and formultations with probiotic microorganisms and medicaments
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US7214370B2 (en) 2000-12-18 2007-05-08 Probiohealth, Llc Prebiotic and preservative uses of oil-emulsified probiotic encapsulations
US6790453B2 (en) 2001-03-14 2004-09-14 Mccormick & Company, Inc. Encapsulation compositions and process for preparing the same
US7815956B2 (en) 2001-04-27 2010-10-19 Pepsico Use of erythritol and D-tagatose in diet or reduced-calorie beverages and food products
US6926907B2 (en) 2001-06-01 2005-08-09 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
CN100366239C (zh) 2001-07-05 2008-02-06 涌永制药株式会社 软胶囊剂
PE20030284A1 (es) 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de bifidobacterium
US20030092724A1 (en) 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
GB0124580D0 (en) 2001-10-12 2001-12-05 Univ Reading New composition
EP3241548A1 (en) 2002-04-05 2017-11-08 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
CA2391422A1 (en) 2002-07-12 2004-01-12 David William Molloy Rifampin (rifadin, rimactone, rifampicin) and doxycycline, (doryx, vibramycin) and the tetracyclines and other compounds currently classified as antibiotics and anti-tuberculous drugs as a treatment to prevent, modify disease progression and/or improve symptoms for neurodegenerative diseases including alzheimers disease, lewy body dementia, schizophrenia,...
IL152127A0 (en) 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease
MXPA06001821A (es) 2003-08-18 2006-05-31 Bio Balance Corp Una composicion probiotica, liquida, estable, preparacion y aplicaciones de la misma.
US7759105B2 (en) 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7749509B2 (en) 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US8016816B2 (en) 2003-09-09 2011-09-13 Convatec Technologies Inc. Fecal management appliance and method and apparatus for introducing same
US7541091B2 (en) 2004-05-18 2009-06-02 M & G Usa Corporation Compartmentalized resin pellets for oxygen scavenging
JP4709838B2 (ja) 2004-08-05 2011-06-29 アニドラル エス．アール．エル． 葉酸産生ビフィドバクテリウム菌株、製剤およびこれらの用途
ATE367821T1 (de) 2004-08-05 2007-08-15 Anidral Srl Folsäure produzierende bifidobacterium bakterienstämme, ihre formulierungen und verwendung
US20060076536A1 (en) 2004-09-29 2006-04-13 Barshied Scott R Oxygen scavenging pharmaceutical package and methods for making same
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
JP4933538B2 (ja) 2005-05-20 2012-05-16 ダウ グローバル テクノロジーズ エルエルシー 無線周波識別標識を用いた経口薬服薬履行監視
US20060275223A1 (en) 2005-06-02 2006-12-07 Burr James B Erythritol compositions for teeth and gums
TWI362949B (en) 2005-09-13 2012-05-01 Bion Tech Inc Intestines dissolving nature is able to bear the hydrochloric acid in gastric juice and wrap up the benefit covered and grow the fungus of makes up
ATE489079T1 (de) 2005-12-29 2010-12-15 Osmotica Kereskedelmi Es Szolgaltata Kft Mehrschichtige tablette mit dreifacher freisetzungskombination
JP5006567B2 (ja) 2006-04-14 2012-08-22 花王株式会社 口腔用固形製剤
US7998510B2 (en) 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
JP2008106066A (ja) 2006-09-25 2008-05-08 Tashiro Yasuaki サポニン及び生菌を含有する組成物
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
PL2136825T3 (pl) 2007-03-01 2014-04-30 Probi Ab Zastosowanie bakterii lactobacillus plantarum do zwiększania różnorodności bakteryjnej
MX2009010418A (es) 2007-03-28 2010-02-18 Alimentary Health Ltd Cepas de bacterias bifidas probioticas.
DK2134833T3 (en) 2007-03-28 2016-06-20 Alimentary Health Ltd Probiotic Bifidobacterium strain
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
CN101686931B (zh) 2007-06-06 2013-06-19 巴斯夫欧洲公司 用于制备可咀嚼片剂和锭剂的药物配制剂
BRPI0812064B8 (pt) 2007-06-06 2021-05-25 Basf Se formulação farmacêutica na forma de aglomerados, comprimidos, e, processo para a produção de uma formulação farmacêutica
BRPI0814175A2 (pt) 2007-07-27 2015-01-20 Cargill Inc Micronização de polióis
EP2183318B1 (en) 2007-08-31 2012-03-07 Invista Technologies S.A R.L. Oxygen scavenging plastic compositions
WO2009041651A1 (ja) 2007-09-27 2009-04-02 Mitsubishi Tanabe Pharma Corporation 速崩壊性固形製剤
PL2572705T3 (pl) 2007-10-01 2018-01-31 Lesvi Laboratorios Sl Tabletki ulegające rozpadowi w jamie ustnej
JP2011500724A (ja) 2007-10-19 2011-01-06 パーデュ リサーチ ファンデーション 結晶性化合物の固体製剤
DK2203551T3 (da) 2007-10-20 2013-10-28 Univ Liege Bifidobakterieart
EP2211879B1 (en) 2007-10-26 2014-05-07 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
JP5258268B2 (ja) 2007-11-19 2013-08-07 フロイント産業株式会社 球形粒の製造方法
WO2009084678A1 (ja) 2007-12-28 2009-07-09 Sawai Pharmaceutical Co., Ltd. 口腔内崩壊錠およびその製造方法
US20100204173A1 (en) 2008-10-02 2010-08-12 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US20100178413A1 (en) 2008-12-17 2010-07-15 Mark Gorris Food-based Supplement Delivery System
WO2010103132A1 (es) 2009-03-10 2010-09-16 Hero España, S.A. Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
US20100255231A1 (en) 2009-04-01 2010-10-07 Multisorb Technologies, Inc. Oxygen scavenging films
ES2425385T3 (es) 2009-04-30 2013-10-15 Actogenix N.V. Crioprotectores para la liofilización de las bacterias de ácido láctico
US20100285164A1 (en) 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
WO2010138439A1 (en) 2009-05-28 2010-12-02 Aptapharma, Inc. Multiparticulate controlled-release selective serotonin reuptake inhibitor formulations
CN201441672U (zh) 2009-07-14 2010-04-28 赵伟华 一次性灌肠装置
US20110045222A1 (en) 2009-08-19 2011-02-24 Eastman Chemical Company Oxygen-scavenging polymer blends suitable for use in packaging
GB0916335D0 (en) 2009-09-17 2009-10-28 Martin W J Medicaments
US20120177650A1 (en) * 2009-09-23 2012-07-12 Borody Thomas J Therapy for enteric infections
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
US20120276149A1 (en) 2009-10-15 2012-11-01 Dan Littman Methods for modulating bacterial infection
US20110218216A1 (en) 2010-01-29 2011-09-08 Kumaravel Vivek Extended release pharmaceutical composition of donepezil
US7888062B1 (en) 2010-02-01 2011-02-15 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
WO2011094027A1 (en) 2010-02-01 2011-08-04 Hlavka Edwin J Bacteriotherapy for clostridium difficile colitis
US8853269B2 (en) 2010-02-04 2014-10-07 Copperhead Chemical Company Inc. Composition and method for treating infections and promoting intestinal health
MX2012010482A (es) 2010-03-10 2013-03-12 Nogra Pharma Ltd Composiciones para lavado de colon y metodos de elaboracion y uso de las mismas.
US9707207B2 (en) 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
CA2807242C (en) 2010-08-04 2017-05-02 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US9386793B2 (en) * 2010-08-20 2016-07-12 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
EP2646567A4 (en) 2010-10-04 2014-03-26 British Columbia Cancer Agency DETECTION OF FUSOBACTERIUM IN A GASTROINTESTINAL SAMPLE TO DIAGNOSE GASTROINTESTINAL CANCER
PT3072524T (pt) 2010-10-07 2018-04-23 California Inst Of Techn Resumo
WO2012098358A1 (en) * 2011-01-20 2012-07-26 Biopharma Technology Ltd Freeze drying method
BR112013022927A2 (pt) * 2011-03-09 2016-12-06 Univ Minnesota composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
US20150374761A1 (en) 2011-03-09 2015-12-31 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
WO2014152484A1 (en) * 2013-03-14 2014-09-25 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
US9050538B2 (en) 2011-05-26 2015-06-09 Sony Corporation Collision detection and motion simulation in game virtual space
WO2013037068A1 (en) 2011-09-14 2013-03-21 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
LT2750682T (lt) 2011-10-11 2016-10-10 Achim Biotherapeutics Ab Kompozicija, apimanti anaerobiškai auginamą žmogaus žarnyno mikroflorą
CA2892588A1 (en) 2011-12-01 2013-06-06 School Corporation, Azabu Veterinary Medicine Educational Institution Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
WO2013090825A1 (en) 2011-12-15 2013-06-20 Pureflora, Inc. Device for the collection, refinement, and administration of gastrointestinal microflora
AU2013256174B2 (en) * 2012-05-02 2017-03-02 Charles River Laboratories, Inc. Viability staining method
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
AU2013308826B2 (en) 2012-08-29 2019-04-18 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
US20150297642A1 (en) 2012-11-26 2015-10-22 Thomas Julius Borody Compositions for the restoration of a fecal microbiota and methods for making and using them
CA2899925A1 (en) * 2013-02-04 2014-08-07 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
EP2968187A4 (en) 2013-03-14 2016-08-17 Therabiome Llc TARGETED ADMINISTRATION OF PROBIOTIC ORGANISMS AND / OR THERAPEUTIC AGENTS IN THE GASTROINTESTINAL TRACT
WO2014176632A1 (en) 2013-04-30 2014-11-06 Borody Thomas J Compositions and methods for treating microbiota-related psychotropic conditions and diseases
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
JP2016530239A (ja) 2013-07-09 2016-09-29 ピュアテック ベンチャーズ、エルエルシー 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物
CA2926466C (en) 2013-10-03 2021-11-16 Frederic Bushman Compositions comprising a defined microbiome and methods of use thereof
CN116370507A (zh) 2013-11-25 2023-07-04 赛里斯治疗公司 协同细菌组合物以及其制造方法和用途
EP3082431A4 (en) 2013-12-16 2017-11-15 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders

Also Published As

Publication number Publication date
JP6966591B2 (ja) 2021-11-17
HK1247840A1 (zh) 2018-10-05
AU2021202100A1 (en) 2021-05-06
US20180153943A1 (en) 2018-06-07
CA2985827A1 (en) 2016-11-17
KR20200087872A (ko) 2020-07-21
US11123377B2 (en) 2021-09-21
US20160331791A1 (en) 2016-11-17
CN114159476A (zh) 2022-03-11
HK1252460A1 (zh) 2019-05-24
CN107949391B (zh) 2021-11-09
AU2016262615A1 (en) 2017-12-07
CN107949391A (zh) 2018-04-20
BR112017024264B1 (pt) 2022-07-12
US20220000939A1 (en) 2022-01-06
EP3294307A1 (en) 2018-03-21
EP3294307A4 (en) 2019-01-23
AU2016262615C1 (en) 2021-06-10
KR20180026376A (ko) 2018-03-12
JP6692897B2 (ja) 2020-05-13
US10821138B2 (en) 2020-11-03
MX2017014488A (es) 2018-06-11
US9901603B2 (en) 2018-02-27
JP2018515617A (ja) 2018-06-14
JP2022009354A (ja) 2022-01-14
JP7301107B2 (ja) 2023-06-30
US20190134106A1 (en) 2019-05-09
WO2016183577A1 (en) 2016-11-17
KR102561989B1 (ko) 2023-07-31
JP2020121996A (ja) 2020-08-13
AU2016262615B2 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
BR112017024264A2 (pt) ?composições para transplante de flora fecal e métodos de preparação e utilização das mesmas, e dispositivos para suaadministração?
ECSP18087725A (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
CO2019008684A2 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas para el tratamiento del cancer
CO2019004137A2 (es) 1,2,4–triazolonas 2,4,5–trisustituidas
MX2019004611A (es) Metodos y composiciones para cambiar la composicion del microbioma de la piel usando mezclas complejas de cepas bacterianas.
CO2019004776A2 (es) Nuevos derivados de quinolina-3-carboxamida antihelmínticos
BR112016018604A2 (pt) Benzimidazol-2-aminas como inibidores de midh1
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
MX2017002954A (es) Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benz oxazol.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
PH12016501807A1 (en) Novel compounds
PH12017501133A1 (en) Pyrazolopyridinamines
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
BR112017019413A2 (pt) combinação de agente bactericida com um agente alcalinizante lisossomotrópico para o tratamento de uma infecção bacteriana
CL2017001539A1 (es) Compuestos indenil, composiciones farmacéuticas y sus usos médicos de los mismos
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
BR112018008781A2 (pt) agente antimicrobiano compreendendo xantohumol e o uso do mesmo em produtos alimentícios
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
MX2016003725A (es) Compuestos y su uso para la preparacion de agentes de formacion de imagen tau y formulaciones para la formacion de imagen tau.
BR112018068794A2 (pt) composição para a prevenção de infecção intramamária e método de prevenção de infecção intramamária
EA201790609A1 (ru) Макроциклические ингибиторы rip2-киназы
BR112017003227A2 (pt) composto, composição farmacêutica e uso de um composto
UY35600A (es) "composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas"
MX2020001808A (es) Nuevos compuestos.
BR112015025288A2 (pt) vacina de campylobacter

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/05/2016, OBSERVADAS AS CONDICOES LEGAIS